Hypercoagulable state mutation analysis in white patients with early first-trimester recurrent pregnancy loss

Fertility and Sterility

Volumn 71, Issue 6, 1999, Pages 1048-1053

  Park, Vicki M ^a  

^a UNIVERSITY OF TENNESSEE HEALTH SCIENCE CENTER   (United States)

Author keywords

Antiphospholipid antibodies; Factor V Leiden; Prothrombin 20210G A; Recurrent pregnancy loss; Thermolabile MTHFR; Thrombosis

Indexed keywords

BLOOD CLOTTING FACTOR 5; CARDIOLIPIN ANTIBODY; PHOSPHOLIPID ANTIBODY; PROTEIN C; PROTHROMBIN;

ADULT; ARTERY THROMBOSIS; ARTICLE; CONTROLLED STUDY; DNA POLYMORPHISM; FEMALE; FETUS WASTAGE; FIRST TRIMESTER PREGNANCY; GENE MUTATION; HOMOZYGOSITY; HUMAN; HYPERCOAGULABILITY; MAJOR CLINICAL STUDY; PERIPHERAL OCCLUSIVE ARTERY DISEASE; POINT MUTATION; PRIORITY JOURNAL; VEIN THROMBOSIS;

ABORTION, HABITUAL; ANTIBODIES, ANTICARDIOLIPIN; AUTOANTIBODIES; BLOOD COAGULATION DISORDERS; CASE-CONTROL STUDIES; DNA MUTATIONAL ANALYSIS; FACTOR V; FEMALE; HUMANS; METHYLENETETRAHYDROFOLATE REDUCTASE (NADPH2); MUTATION; OXIDOREDUCTASES ACTING ON CH-NH GROUP DONORS; PHOSPHATIDYLSERINES; POLYMERASE CHAIN REACTION; PREGNANCY; PREGNANCY TRIMESTER, FIRST; PROSPECTIVE STUDIES; PROTHROMBIN;

EID: 0033153189     PISSN: 00150282     EISSN: None     Source Type: Journal    
DOI: 10.1016/S0015-0282(99)00133-8     Document Type: Article

References (31)

1. Branch D.W., Silver R.M., Blackwell J.L., Reading J.C., Scott J.R. Outcome of treated pregnancies in women with antiphospholipid syndrome an update of the Utah experience . Obstet Gynecol. 80:1992;614-620.
2. Kutteh W.H. Antiphospholipid antibody-associated recurrent pregnancy loss treatment with heparin and low-dose aspirin is superior to low-dose aspirin alone . Obstet Gynecol. 174:1996;1584-1589.
3. Cariou R., Tobelem G., Soria C., Caen J. Inhibition of protein C activation by endothelial cells in the presence of lupus anticoagulant. N Engl J Med. 314:1986;1193-1194.
4. Borrell M., Sala N., de Castellarnau C., Lopez S., Gari M., Fontcuberta J. Immunoglobulin fractions isolated from patients with antiphospholipid antibodies prevent the inactivation of factor Va by activated protein C on human endothelial cells. Thromb Haemost. 68:1992;268-272.
5. Malia R.G., Kitchen S., Greaves M., Preston F.E. Inhibition of activated protein C and its cofactor protein S by antiphospholipid antibodies. Br J Haematol. 76:1990;101-107.
6. Rees D.C., Cox M., Clegg J.B. World distribution of factor V Leiden. Lancet. 346:1995;1133-1134.
7. Dahlbäck B. Physiological anticoagulation resistance to activated protein C and venous thromboembolism . J Clin Invest. 94:1994;923-927.
8. 506 of factor V. Lancet. 343:1994;1535-1536.
9. Griffin J.H., Evatt B., Wideman C., Fernandez J.A. Anticoagulant protein C pathway defective in majority of thrombophilic patients. Blood. 82:1993;1989-1993.
10. Ridker P.M., Miletich J.P., Buring J.E., Ariyo A.A., Price D.T., Manson J.E., et al. Factor V Leiden mutation as a risk factor for recurrent pregnancy loss. Ann Intern Med. 128:1998;1000-1003.
11. Arruda V.R., von Zuben P.M., Chiaparini L.C., Annichino-Bizzachi J.M., Costa F.F. The mutation Ala677→Val in the methylene tetrahydrofolate reductase gene a risk factor for arterial disease and venous thrombosis . Thromb Haemost. 77:1997;818-821.
12. Guttormsen A.B., Ueland P.M., Nesthus I., Nygärd O., Schneede J., Vollset S.E. Determinants and vitamin responsiveness of intermediate hyperhomocysteinemia (≥40 μmol/liter). J Clin Invest. 98:1996;2174-2183.
13. Poort S.R., Rosendaal F.R., Reitsma P.H., Bertina R.M. A common genetic variation in the 3′-untranslated region of the prothrombin gene is associated with elevated plasma prothrombin levels and an increase in venous thrombosis. Blood. 88:1996;3698-3703.
14. Rosendaal F.R., Siscovick D.S., Schwartz S.M., Psaty B.M., Raghunathan T.E., Vos H.L. A common prothrombin variant (20210 G to A) increases the risk of myocardial infarction in young women. Blood. 90:1997;1747-1750.
15. Ridker P.M., Miletich J.P., Buring J.E. Ethnic distribution of factor V Leiden in 4047 men and women implications for venous thromboembolism screening . J Am Med Assoc. 277:1997;1305-1307.
16. Bertina R.M., Koeleman B.P.C., Koster T., Rosendaal F.R., Dirven R.J., de Ronde H., et al. Mutation in blood coagulation factor V associated with resistance to activated protein C. Nature. 369:1994;64-68.
17. Frosst P., Blom H.J., Milos R., Goyette P., Sheppard C.A., Matthews R.G., et al. A candidate genetic risk factor for vascular disease a common mutation in methylenetetrahydrofolate reductase . Nat Genet. 10:1995;111-113.
18. Rosendaal F.R., Doggen C.J.M., Zivelin A., Arruda V.R., Aiach M., Siscovick D.S., et al. Geographic distribution of the 20210G to A prothrombin variant. Thromb Haemost. 79:1998;706-708.
19. Dahlbäck B. Molecular genetics of thrombophilias factor V gene mutation causing resistance to activated protein C as a basis of the hypercoagulable state. J Clin Lab Med. 125:1995;566-571.
20. Hallak M., Senderowicz J., Cassel A., Shapira C., Aghai E., Auslender R., et al. Activated protein C resistance (factor V Leiden) associated with thrombosis in pregnancy. Am J Obstet Gynecol. 176:1997;889-893.
21. Grandone E., Margaglione M., Colaizzo D., d'Addedda M., Cappucci G., Vecchione G., et al. Factor V Leiden is associated with repeated and recurrent unexplained fetal losses. Thromb Haemost. 77:1997;822-824.
22. Dizon-Townson D.S., Kinney S., Branch D.W., Wand K. The factor V Leiden mutation is not a common cause of recurrent miscarriage. J Reprod Immunol. 34:1997;217-223.
23. Preston F.E., Rosendaal F.R., Walker I.D., Briët E., Berntorp E., Conard J., et al. Increased fetal loss in women with heritable thrombophilia. Lancet. 348:1996;913-916.
24. Rai R., Regan L., Hadley E., Dave M., Cohen H. Second-trimester pregnancy loss is associated with activated protein C resistance. Br J Haematol. 92:1996;489-490.
25. Walker M.C., Garner P.R., Keely E.J., Rock G.A., Reis M.D. Changes in activated protein C resistance during normal pregnancy. Am J Obstet Gynecol. 177:1997;162-169.
26. Grandone E., Margaglione M., Colaizzo D., d'Addedda M., D'Andrea G., Pavone G., et al. Methylene tetrahydrofolate reductase (MTHFR) 677T→C mutation and unexplained early pregnancy loss. Thromb Haemost. 79:1998;1056-1057.
27. Wouters M.G., Boers G.H., Blom H.J., Trijbels F.J., Thomas C.M., Borm G.F., et al. Hyperhomocysteinemia a risk factor in women with unexplained recurrent early pregnancy loss . Fertil Steril. 60:1993;820-825.
28. Nelen W.L., Blom H.J., Thomas C.M., Steegers E.A., Boers G.H., Eskes T.K. Methylenetetrahydrofolate reductase polymorphism affects the change in homocysteine and folate concentrations resulting from low dose folic acid supplementation in women with unexplained recurrent miscarriages. J Nutr. 128:1998;1336-1341.
29. Quere I., Bellet H., Hoffet M., Janbon C., Mares P., Gris J.C. A woman with five consecutive fetal deaths case report and retrospective analysis of hyperhomocysteinemia prevalence in 100 consecutive women with recurrent miscarriages . Fertil Steril. 69:1998;152-154.
30. Metz J., Kloss M., O'Malley C.J., Rockman S.P., DeRosa L., Doig R., et al. Prevalence of factor V Leiden is not increased in women with recurrent miscarriage. Clin Appl Thromb Hemostat. 3:1997;137-140.
31. Pauer H.U., Neesen J., Hinney B. Factor V Leiden and its relevance in patients with recurrent abortions. Am J Obstet Gynecol. 178:1998;629.